top of page


NexEos Bio Announces Pipeline Expansion

MALVERN, PA., June 19, 2024  – NexEos Bio is excited to announce an expansion of our R&D pipeline of diagnostics and therapeutics for eosinophil and eosinophil cationic protein-related diseases. See for more information.


Our lead diagnostic NDX-3324, an oral, radiolabeled imaging agent for the detection, diagnosis and monitoring of Eosinophilic Esophagitis, is progressing into Phase II clinical trials. Our lead therapeutic NTX-1024, a topical eye drop for the treatment of Eosinophilic Conjunctivitis (including Atopic Keratoconjunctivitis, Perennial Allergic Conjunctivitis, Vernal Keratoconjunctivitis - VKC) is completing pre-clinical work and beginning to explore proof of concept trial options, including preparations for a first-in-human study in Mexico  for the orphan disease, VKC.


On the research side, we have emerging technologies, including NDX-LmAb and NTX-200, which target in vitro detection and modulation, respectively, of preterm labor.   Over 350,000 babies are born preterm in the US each year.  Finally, NDX-600, a systemic imaging agent, along with NTX-600,  aim to detect and treat acute, severe inflammatory conditions caused by eosinophils throughout the body which are a challenge to diagnose and treat today. All of the technologies in the NexEos pipeline  were developed under the leadership of our Chief Scientific Officer, Dr. Gerald Gleich.


“Dr Gleich is one of the most inspirational people I have come to know, incredibly experienced with literally decades of work in the eosinophil space that he shares openly and humbly,” said Steve Tullman, NexEos, Chairman and CEO.  “His depth of knowledge, and collaboration, are what has created the basis for the NexEos programs, all of which are novel and target important unmet medical needs for patients and healthcare providers.”


NexEos Bio, while still in early days of development of our expanded pipeline, is optimistic about our ability to better illuminate the role of eosinophils in human biology and develop technologies to better diagnose and treat diseases driven by eosinophil and cationic proteins to allow our patients to enjoy a brighter future.

bottom of page